FDA Investigators Play Fast And Loose With Quality System Inspection Technique, Experts Say – But Is It Par For The Course?
• By Shawn M. Schmitt
US FDA’s Quality System Inspection Technique – or QSIT – isn’t being followed to the “T” by many agency investigators, say industry experts, including two who authored the auditing approach in 1999. Sources tell Medtech Insight that QSIT, designed to ensure that investigators look at the most important compliance issues and ask pertinent questions linked to four major quality system subsystems, is routinely bypassed by investigators bent on inspecting their own way. But it’s not unreasonable for investigators to deviate from QSIT as they follow leads wherever they may go, says a former director of FDA’s Investigations Branch who left the agency in June. Meanwhile, a key player in the development of the Quality System Inspection Technique, Tim Wells, explains why he’s drafting a “new” QSIT for industry use.
Two authors of US FDA’s Quality System Inspection Technique say too many agency investigators aren’t always following the auditing approach when conducting facility inspections, often catching device manufacturers by surprise as they manage onsite FDA audits.
The claims come as one of the authors – Tim Wells – says QSIT is outdated and desperately needs a facelift; he is in the process of creating his own...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.
During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.
Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.
